Using cardiac magnetic resonance imaging to detect early changes in heart muscle that may help predict patients who are at risk of developing toxicity from anthracycline chemotherapy.
Use of myocardial tissue characterization by cardiac magnetic resonance imaging to predict left ventricular dysfunction in patients undergoing anthracycline chemotherapy.
Dr James Hare
50 participants
Oct 12, 2012
Observational
Conditions
Summary
Aim is to assess whether a novel cardiac magnetic resonance imaging (CMR) technique, T2 mapping, can identify myocardial edema as a marker of myocardial injury and be used as a predictor of cardiac dysfunction in patients undergoing anthracycline chemotherapy.
Eligibility
Inclusion Criteria2
- Patient referred for anthracycline chemotherapy (i.e. for lymphoma)
- Healthy controls
Exclusion Criteria5
- Acute renal failure or chronic renal failure manifest by GFR<60 ml/kg/1.73m2.
- Contraindication to MRI scanning.
- Known hypersensitivity to gadolinium.
- Atrial fibrillation at baseline.
- Pregnancy.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Magnetic resonance imaging scan of the heart (60 minutes duration) before chemotherapy, on completion of chemotherapy cycles (~3 months) and at 1 year after commencement of chemotherapy.We will use novel MRI sequences (T1 and T2 mapping) which aim to quantify specific magnetic properties of the heart muscle that related to myocardial edema (seen in inflammation) and fibrosis.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12612001100886